Department of Nuclear Medicine, University Hospital Essen, Essen, Germany.
Eur J Nucl Med Mol Imaging. 2011 May;38 Suppl 1:S48-56. doi: 10.1007/s00259-011-1773-5. Epub 2011 Apr 12.
(124)I-PET/CT has a high clinical potential in patients with differentiated thyroid cancer (DTC). Two aspects deserve special mention: staging of recurrent or residual disease and pretherapy dosimetry. Used in combination (124)I-PET and CT allows foci of highly specific (124)I uptake to be localized with a low radiation dose, which is specifically important in pretherapy diagnostics. In addition in the combination of FDG-PET and CT non-iodine-avid lesions may be detected and may be discriminated from simultaneously occurring iodine-positive lesions. In clinical applications, the pretherapy (124)I-PET dosimetry may result in a significant alteration in the therapeutic procedure compared to standard therapy using fixed therapeutic activities. In this context, (124)I-PET dosimetry is a useful procedure especially in advanced DTC, and allows the administration of safer and more effective radioiodine activities as well as earlier multimodal interventions compared to standard empirical protocols. This review summarizes the clinical data on (124)I-PET/CT in patients with DTC, and addresses future prospects.
(124)I-PET/CT 在分化型甲状腺癌（DTC）患者中有很高的临床应用潜力。有两个方面值得特别提及：复发性或残留疾病的分期和治疗前剂量测定。(124)I-PET 和 CT 的联合使用可以用低辐射剂量定位高度特异性的(124)I 摄取病灶，这在治疗前诊断中特别重要。此外，在 FDG-PET 和 CT 的联合应用中，可能会发现非碘摄取病变，并与同时发生的碘阳性病变区分开来。在临床应用中，与使用固定治疗活性的标准治疗相比，治疗前(124)I-PET 剂量测定可能会导致治疗方案的显著改变。在这种情况下，(124)I-PET 剂量测定是一种有用的方法，特别是在晚期 DTC 中，与标准经验性方案相比，它允许给予更安全、更有效的放射性碘活性以及更早的多模式干预。这篇综述总结了(124)I-PET/CT 在 DTC 患者中的临床数据，并探讨了未来的前景。
